key: cord-0027337-ivwnmwjp
authors: Lacombe, Marouschka; Bedane, Christophe; Delaumenie, Stéphanie; Bernard, Philippe
title: Nivolumab-induced multiple morphea associated with eosinophilic fasciitis
date: 2022-02-17
journal: Eur J Dermatol
DOI: 10.1684/ejd.2021.4181
sha: e81e95c85a8cd027cfefb0df28c677bd1c8f3dc5
doc_id: 27337
cord_uid: ivwnmwjp

nan

Levine RM, Tattersall IW, Gaudio PA, King BA. Cicatrizing blepharoconjunctivitis occurring during dupilumab treatment and a proposed algorithm for its management. JAMA Dermatol 2018; 154: 1485-6. 

Among immune checkpoint inhibitors, antibodies against target programmed cell death protein 1 (PD1), including nivolumab, have dramatically improved the survival of patients with melanoma along with targeted therapies [1] . Cutaneous and rheumatic immune-related adverse events (irAEs) with anti-PD-1 antibodies are directly related to their mechanism of action, are varied in nature and may be severe [2] . In 2018, a 50-year-old male was treated by surgical excision for a nodular melanoma of the leg with Breslow thickness of 24 mm, with positive sentinel lymph node. Adjuvant therapy with nivolumab (480 mg i.v. every month) was started in September 2018. Five months later, the patient complained about respiratory symptoms including cough and dyspnoea. At the same time, laboratory tests revealed blood eosinophilia (947/mm 3 ). Bronchoalveolar lavage was unfortunately impossible to perform due to the patient's clinical intolerance. Given the gradual increase in eosinophils and the persistence of respiratory symptoms, nivolumab was discontinued in June 2019 while radiological examinations (tomodensitometry and TEP scan) remained normal. Whereas respiratory symptoms gradually disappeared, blood eosinophilia continued to increase (1892/mm 3 ). Other routine laboratory tests were normal. In July 2019, the patient complained about a symmetrical painful swelling of the lower limbs and appearance of multiple hypochromic plaque-type morphea on the neck ( figure 1A) . Complementary investigations did not reveal any renal, vascular or cardiac abnormalities. In September 2019, oedematous and bullous skin lesions along with progressive induration and thickening of the skin and soft tissues appeared on his legs and arms (figure 1B). A skin biopsy showed dermal-epidermal cleavage with epidermal spongiosis without a significant inflammatory infiltrate. As the leg pain became unbearable despite potent analgesics, a deep skin biopsy was performed and showed fibrous oedema of hypodermic septa associated with a dense infiltrate of eosinophils ( figure 1C) . MRI showed the presence of myositis and fasciitis involving the muscles of the four limbs without muscular atrophy. Concomitantly, blood eosinophilia continued to increase (2030/mm 3 ) but CK levels remained normal. Taken together, these results were consistent with eosinophilic fasciitis. Treatment with prednisone (1 mg/kg/day) was started, rapidly combined with methotrexate (0.3 mg/kg/week). In March 2020, as the patient did not totally recover, monthly intravenous immunoglobulins were added and progressively improved the skin manifestations. Currently (August 2021), the patient is still treated with spaced infusions of immunoglobulins (every six weeks) and prednisone (10 mg daily) allowing major and long-lasting improvement of his fasciitis. While the typical irAEs due to anti-PD1 immunotherapy, namely colitis, thyroiditis and hepatitis, are well recognized, cutaneous irAEs are varied and may be difficult to diagnose. This is particularly the case for disorders associated with the scleroderma spectrum due to anti-PD-1, as reported in the literature, which include morphea, sclerodermoid changes, eosinophilic fasciitis, and lichen sclerosis [3] . According to recent reports, it seems that dermatologic and rheumatic manifestations occur later in the course of immunotherapy, as compared to other irAEs, and are significantly preceded by a high level of eosinophilia, as in our case [4] . Based on Terrier et al.'s review of the WHO pharmacovigilance database, VigiBase, 35 cases of scleroderma with immune checkpoint inhibition therapy have been reported [5] . About 20 cases of fasciitis induced by immunotherapy have been described in the literature, but on closer inspection, only 12 corresponded to true Shulman fasciitis [6] . The most frequently reported treatment for eosinophilic fasciitis induced by immunotherapy is corticosteroid therapy at doses ≥20 mg/d [7, 8] . Despite its efficacy, it seems to reduce the therapeutic effect of immunotherapy and induces steroid complications [9] . In order to minimise this, steroid sparing may be implanted by adding treatments such as methotrexate or intravenous immunoglobulins, as in our case. Any decision to administer potent systemic immunosuppression should be carefully balanced against the risk of promoting melanoma progression.

To the best of our knowledge, we report the first case of multiple morphea associated with eosinophilic fasciitis occurring after nivolumab therapy for a malignant melanoma. Of note, both skin conditions can appear and evolve even if the treatment is stopped, as shown in our case. In addition, the presence of rheumatic muscle symptoms, such as muscle pain and swelling or appearance of sclerodermoid plaques, should lead to heightened awareness in order to diagnose and treat this pathology as soon as possible. The concomitant development of symptomatic inflammatory myositis with fasciitis, morphea and elevated eosinophils appears to be a new adverse effect of anti-PD-1 immunotherapy. Dupilumab, an emerging therapeutic choice for recalcitrant subepidermal autoimmune bullous diseases: a case series of three patients Subepidermal autoimmune bullous diseases (SABD) comprise a large group of chronic dermatoses, including namely (among others) bullous pemphigoid (BP), epidermolysis bullosa acquisita (EBA) and anti-p200 pemphigoid [1] . These diseases are characterized by the presence of autoantibodies that target distinct antigens of the basement membrane zone. Treatment of SABD is complex and different according to each particular disease. In BP, firstline therapy includes topical and systemic corticosteroids, while immunosuppressants are considered in resistant cases. However, these treatments can cause adverse events and pose additional risks in terms of COVID-19 [2] . A recent multicentre study suggested that dupilumab, an interleukin (IL)-4 receptor ␣-antagonist blocking IL-4 and IL-13 cytokine-induced responses, may be a novel therapy for BP [3] . The efficacy and safety of dupilumab in recalcitrant SABD remains to be further evaluated. We report three SABD cases with extensive lesions who did not respond to conventional therapies but improved after treatment with dupilumab. All patients were diagnosed with SABD based on clinical manifestation, histology and direct immunofluorescence (supplementary table 1 ). The first patient had an inadequate response to various treatments, including systemic corticosteroids and immunosuppressive agents, and had multiple flares with corticosteroid tapering. She had a history of psychiatric disorder but had been in remission for eight years with no medication. During the last relapse ( figure 1A, B) , her disease progressed under a combined therapy of methylprednisolone (MEP) or dexamethasone (equivalent to 1.5-2.5 mg/kg/d prednisone), intravenous immunoglobulin (IVIG) and cyclophosphamide (CTX), and she suffered from mental and behavioural disorders. Dupilumab (600 mg) was administrated subcutaneously (SC), followed by 300 mg every other week for one month, in combination with prednisone at 0.75 mg/kg/d and CTX. The skin lesions improved rapidly within one week. After a month of dupilumab therapy, the patient's disease had cleared. She was successfully tapered off prednisone over 12 weeks ( figure 1C, D) . The second patient was diagnosed with BP considering serum positivity of anti-BP180 antibodies. He had a poor response to a combination of MEP (equivalent to 1.5-2.2 mg/kg/d prednisone), IVIG, methotrexate (MTX) and cyclosporine for three weeks ( figure 1E, F) . His HBsAg test was positive with high copies of HBV. Therefore, 600 mg dupilumab was added together with MEP, MTX and cyclosporine. The skin lesions were controlled with no new blisters within one week ( figure 1G, H) . Although dupilumab was discontinued due to cost, the patient showed

Immunotherapy of melanoma

Rheumatic diseases associated with immune checkpoint inhibitors in cancer immunotherapy

Nivolumab-induced plaque morphea in a malign melanoma patient

Checkpoint inhibitor-induced eosinophilic fasciitis following high eosinophilia associated with complete response

Risk of scleroderma according to the type of immune checkpoint inhibitors

Rheumatic manifestations among cancer patients treated with immune checkpoint inhibitors

Eosinophilic fasciitis following checkpoint inhibitor therapy: four cases and a review of literature